Macular Society Newsletter

This month’s newsletter from the Macular Society is now out – you can read it here

Below are some of the headline stories in the newsletter:

Second drug for dry AMD becomes available in the US
Another new drug to treat late-stage dry age-related macular degeneration (AMD) has been approved for use in the US. Izervay has proven in clinical trials to be effective at reducing the rate of progression of the disease in its late stages. The FDA-approved drug is not only the second drug to receive approval this year, but also the second drug ever to be approved for treating dry AMD.

Understanding the mysteries surrounding Charles Bonnet syndrome
Have you experienced visual hallucinations as a result of sight loss? So much mystery still surrounds these hallucinations, known as Charles Bonnet syndrome. Optometrist and researcher, professor Jasleen Jolly of the Vision and Eye Research Institute at Anglia Ruskin University, has revealed more about the projects she’s working on, which hope to shine light on this condition.

How did Covid-19 affect the mental health of patients with degenerative eye conditions?
The after effects of the Covid-19 pandemic are being studied by researchers across the globe. But, what impact did it have on the mental health of patients with degenerative eye conditions? Dr Hari Jayaram, associate professor at the Institute of Ophthalmology and consultant ophthalmic surgeon at Moorfields Eye Hospital, has been researching this topic. He joins us for September’s first My Macular and Me webinar to reveal more about his findings.

What could laser treatment mean for your vision?
Dr Liam Sullivan, consultant ophthalmologist at Cambridge University Hospital, will be discussing laser treatment for patients with retinal conditions, such as diabetic retinopathy and retinal vein occlusion in our second webinar of the month. Dr Sullivan will explore the various types of laser and when they are used. Join us to find out what to expect from treatment and what it could mean for your vision.